OmniFlu HA Kit Detects and Quantifies Hemagglutinin for Vaccine Manufacturers

OmniFlu HA is a validated, off-the-shelf kit for seasonal influenza vaccine manufacturers to detect and quantify hemagglutinin (HA).

Every flu season, the World Health Organization releases influenza strain recommendations that often require updates to current analytical methods. OmniFlu HA quantifies 4 seasonal HA antigens (A/H1, A/H3, B/Victoria, and B/Yamagata). All kits are specific for the current flu season—saving manufacturers months of development time.

Based on the company's VaxArray Platform and leveraging more than 300 influenza antibodies from the InDevR library, OmniFlu allows vaccine developers to harness microarray-based multiplexed immunoassays to streamline vaccine characterization, reducing their validation bottlenecks and accelerating analytical development. It analyzes up to 64 samples with results in less than 2 hours.

The OmniFlu HA microarray contains multiple antibodies targeting each vaccine component for comprehensive multiplexed detection of influenza HA from a wide range of vaccine production systems including egg-based, cell-based, recombinant, and in vitro expressed protein for application to mRNA vaccines. Capture reagents are prevalidated for high specificity to the A/H1, A/H3, B/Victoria, and B/Yamagata components across every biannual strain recommendation made by the World Health Organization.

Features:

• Ready-to-use kit eliminates sourcing reagents and establishing new protocols
• Every seasonal strain is validated for use on the World Health Organization (WHO)-recommended influenza strains
• A tailored panel of validated capture reagents enables egg-based, cell-based, or recombinant influenza HA analysis from a single kit

InDevR, Inc.
Boulder, Colorado
(303) 402-9100
[email protected]
www.indevr.com